Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 4/2010

01-08-2010

Comorbidity, Hospitalization, and Mortality in COPD: Results from a Longitudinal Study

Authors: Claudio Terzano, Vittoria Conti, Fabio Di Stefano, Angelo Petroianni, Daniela Ceccarelli, Elda Graziani, Salvatore Mariotta, Alberto Ricci, Antonio Vitarelli, Giovanni Puglisi, Corrado De Vito, Paolo Villari, Luigi Allegra

Published in: Lung | Issue 4/2010

Login to get access

Abstract

We evaluated comorbidity, hospitalization, and mortality in chronic obstructive pulmonary disease (COPD), with special attention to risk factors for frequent hospitalizations (more than three during the follow-up period), and prognostic factors for death. Two hundred eighty-eight consecutive COPD patients admitted to respiratory medicine wards in four hospitals for acute exacerbation were enrolled from 1999 to 2000 in a prospective longitudinal study, and followed up until December 2007. The Charlson index without age was used to quantify comorbidity. Clinical and biochemical parameters and pulmonary function data were evaluated as potential predictive factors of mortality and hospitalization. FEV1, RV, PaO2, and PaCO2 were used to develop an index of respiratory functional impairment (REFI index). Hypertension was the most common comorbidity (64.2%), followed by chronic renal failure (26.3%), diabetes mellitus (25.3%), and cardiac diseases (22.1%). Main causes of hospitalization were exacerbation of COPD (41.2%) and cardiovascular disease (34.4%). Most of the 56 deaths (19.4%) were due to cardiovascular disease (67.8%). Mortality risk depended on age, current smoking, FEV1, PaO2, the REFI index, the presence of cor pulmonale, ischemic heart disease, and lung cancer. Number and length of hospital admissions depended on the degree of dyspnea and REFI index. The correct management of respiratory disease and the implementation of aggressive strategies to prevent or treat comorbidities are necessary for better care of COPD patients.
Literature
1.
Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J (1995) Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 8:1398–1420CrossRefPubMed
2.
Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R (1997) Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10:2794–2800CrossRefPubMed
3.
Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 93:391–398
4.
Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL (1996) Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9:431–435CrossRefPubMed
5.
Nishimura K, Izumi T, Tsukino M, Oga T (2002) Dyspnea is a better predictor of 5 year survival than airway obstruction in patients with COPD. Chest 121:1434–1440CrossRefPubMed
6.
Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP (1999) Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1856–1861PubMed
7.
Holguin F, Folch E, Redd SC, Mannino DM (2005) Comorbidity and mortality in COPD related hospitalizations in the United States, 1979 to 2001. Chest 128:2005–2011CrossRefPubMed
8.
Huiart L, Ernst P, Suissa S (2005) Cardiovascular morbidity and mortality in COPD. Chest 128:2640–2646CrossRefPubMed
9.
Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD (2005) COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 128:2068–2075CrossRefPubMed
10.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565CrossRefPubMed
11.
Peng RD, Chang HH, Bell ML, McDermott A, Zeger SL, Samet JM, Dominici F (2008) Coarse particulate matter air pollution and hospital admissions for cardiovascular and respiratory diseases among medicare patients. JAMA 299:2172–2179CrossRefPubMed
12.
Dominici F, Peng RD, Bell ML, Pham L, McDermott A, Zeger SL, Samet JM (2006) Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. JAMA 295:1127–1134CrossRefPubMed
13.
Jennings JH, Digiovine B, Obeid D, Frank C (2009) The association between depressive symptoms and acute exacerbations of COPD. Lung 187:128–135CrossRefPubMed
14.
COPD Guideline Group of the Standards of Care Committee of the BTS (1997) BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 52(Suppl 5):S1–S28
15.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefPubMed
16.
Charlson ME, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRefPubMed
17.
Newth CJ, Enright P, Johnson RL Jr (1997) Multiple breath nitrogen washout techniques: including measurements with patients on ventilators. Eur Respir J 10:2174–2185CrossRefPubMed
18.
19.
Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH (1997) Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 155:1278–1282PubMed
20.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
21.
Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106:506–512CrossRefPubMed
22.
Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241–2247PubMed
23.
Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD (2001) Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103:2323–2327PubMed
24.
Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D (1999) Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19:538–545PubMed
25.
Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, Niederman MS (2000) Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 117:662–671CrossRefPubMed
26.
Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, Plaza V, Prieto L, Antò JM (1997) Chronic obstructive pulmonary disease stage and health related quality of life. Ann Intern Med 127:1072–1079PubMed
27.
Anthonisen NR, Wright EC, Hodgkin JE (1986) Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 133:14–20PubMed
28.
Burrows B (1991) Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1:340–345
29.
Dykstra BJ, Scanlon PD, Kester MM, Beck KC, Enright PL (1999) Lung volumes in 4, 774 patients with obstructive lung disease. Chest 115:68–74CrossRefPubMed
30.
Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York
31.
Fuso L, Antonelli Incalzi R, Pistelli R, Muzzolon R, Valente S, Pagliari G, Ghiozzi F, Ciappi G (1995) Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 98:272–277CrossRefPubMed
32.
Buch P, Friberg J, Scharling H, Lange P, Prescott E (2003) Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 21:1012–1016CrossRefPubMed
33.
Christensen S, Thomsen RW, Tørring ML, Riis A, Nørgaard M, Sørensen HT (2008) Impact of COPD on outcome among patients with complicated peptic ulcer. Chest 133:1360–1366CrossRefPubMed
34.
MacNee W (1994) Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med 150:1158–1168PubMed
35.
Dubois P, Jamart J, Machiels J, Smeets F, Lulling J (1994) Prognosis of severely hypoxemic patients receiving long term oxygen therapy. Chest 105:469–474CrossRefPubMed
36.
Ashutosh K, Dunsky M (1987) Non invasive test for responsiveness of pulmonary hypertension to oxygen. Prediction of survival in patients with chronic obstructive lung disease and cor pulmonale. Chest 92:392–399CrossRef
37.
Skawarski K, MacNee W, Wraith PK, Sliwinski P, Zielinski J (1991) Predictors of survival in patients with chronic obstructive pulmonary disease treated with long term oxygen therapy. Chest 100:1522–1527CrossRef
38.
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005) The effects of a smoking cessation intervention on 14.5-year mortality. A randomized clinical trial. Ann Intern Med 142:233–239PubMed
39.
Resnick HE, Lindsay RS, McDermott M, Devereux RB, Jones KL, Fabsitz R, Howard BW (2004) Relationship of high and low ankle brachial index to all cause and cardiovascular disease mortality. The strong heart study. Circulation 109:733–739CrossRefPubMed
40.
Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM (1996) Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 313:711–715PubMed
41.
Leith DE, Mead J (1967) Mechanisms determining residual volume of the lungs in normal subjects. J Appl Physiol 23:221–227PubMed
42.
43.
Marin JM, Carrizo SJ, Casanova C, Martinez-Camblor P, Soriano JB, Agusti AG, Celli BR (2009) Prediction of risk of COPD exacerbations by the BODE index. Respir Med 103:373–378CrossRefPubMed
44.
Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW (2006) Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61:284–289CrossRefPubMed
45.
McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassaloti J, Whaley-Connell AT, Brenner RM, Bakris GL (2008) KEEP Investigators (2008) Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J 156:277–283CrossRefPubMed
46.
Thomas F, Blacher J, Benetos A, Safar ME, Pannier B (2008) Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality. J Hypertens 26:1072–1077CrossRefPubMed
47.
Golomb BA, Dang TT, Criqui MH (2006) Peripheral arterial disease: morbidity and mortality implications. Circulation 114:688–699CrossRefPubMed
48.
Menon B, Gurnani M, Aggarwal B (2008) Comparison of outpatient visits and hospitalisations, in patients with chronic obstructive pulmonary disease, before and after influenza vaccination. Int J Clin Pract 62:593–598CrossRefPubMed
Metadata
Title
Comorbidity, Hospitalization, and Mortality in COPD: Results from a Longitudinal Study
Authors
Claudio Terzano
Vittoria Conti
Fabio Di Stefano
Angelo Petroianni
Daniela Ceccarelli
Elda Graziani
Salvatore Mariotta
Alberto Ricci
Antonio Vitarelli
Giovanni Puglisi
Corrado De Vito
Paolo Villari
Luigi Allegra
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Lung / Issue 4/2010
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-009-9222-y

Other articles of this Issue 4/2010

Lung 4/2010 Go to the issue

ReviewPaper

Nontuberculous Mycobacteria and the Lung: From Suspicion to Treatment

OriginalPaper

Continuous Positive Airway Pressure Improves Sleep Apnea Associated Fatty Liver

OriginalPaper

Nontuberculous Mycobacterial Lung Infections in Ontario, Canada: Clinical and Microbiological Characteristics

OriginalPaper

Comparison of T-Cell Interferon-γ Release Assays for Mycobacterium tuberculosis-Specific Antigens in Patients with Active and Latent Tuberculosis

OriginalPaper

Cheyne-Stokes Respiration and Prognosis in Modern-Treated Congestive Heart Failure

Report

A Novel BMPR2 Mutation Associated with Pulmonary Arterial Hypertension in an Octogenarian
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits